Publications - Dr. Andrea Edginton

Selected Publications

2024

  1. Matino D, Germini F, Chan A, Decker K, Iserman E, Chelle P, Edginton A, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with hemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. Accepted. 2024
  2. Yeung CHT, Autmizguine J, Dalvi P, Denoncourt A, Lto S, Katz P, Rahman M, Theoret Y, Edginton AN. Maternal Ezetimibe Concentrations Measured in Breast Milk and its Use in Breastfeeding Infant Exposure Predictions. Clinical Pharmacokinetics. 2024 Jan 26. doi: 10.1007/s40262-023-01345-0. Epub ahead of print. PMID: 38278872.

2023

  1. Dubinsky SDJ, Watt KM, Imburgia CE, Mcknite AM, Hunt JP, Rice C, Rower JE, Edginton AN. Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis. Critical Care Explorations. 2023 Dec 14;5(12):e1010. doi: 10.1097/CCE.0000000000001010. PMID: 38107537; PMCID: PMC10723863.
  2. Hunt JP, Dubinsky S, McKnite AM, Cheung KWK, van Groen BD, Giacomini KM, de Wildt SN, Edginton AN, Watt KM. Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT Pharmacometrics & Systems Pharmacology. 2023 Dec 29. doi: 10.1002/psp4.13102. Epub ahead of print. PMID: 38156758.
  3. Yeung CHT, Bertrand KA, Best BM, Capparelli E, Chambers CD, Hajducek DM, Hamadeh A, Ito S, Momper JD, Edginton AN. Cannabidiol Exposure Through Maternal Marijuana Use: Predictions in Breastfed Infants. Clinical Pharmacokinetics. 2023 Nov;62(11):1611-1619. doi: 10.1007/s40262-023-01307-6. Epub 2023 Sep 21. PMID: 37735347; PMCID: PMC10659070.
  4. Hamadeh A, Najjar A, Troutman J, Edginton A. Enhancement of Skin Permeability Prediction through PBPK Modeling, Bayesian Inference, and Experiment Design. Pharmaceutics. 2023 Nov 24;15(12):2667. doi: 10.3390/pharmaceutics15122667. PMID: 38140008; PMCID: PMC10747907.
  5. Hamadeh A, Nash JF, Bialk H, Styczynski P, Troutman J, Edginton A. Mechanistic skin modeling of plasma concentrations of sunscreen active ingredients following facial application. Journal of Pharmaceutical Sciences. 2023 Sep 26:S0022-3549(23)00379-9. doi: 10.1016/j.xphs.2023.09.017. Epub ahead of print. PMID: 37769994.
  6. Yeung C, Bertrand K, Best B, Capparelli E, Chambers C, Ito S, Momper J, Edginton A. Cannabidiol exposures in breastfed infants compared to children as predicted by physiologically based pharmacokinetic modeling. Clinical Pharmacology & Therapeutics. 2023;113(S1):S37.
  7. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023;29(2):488-497. doi:10.1111/hae.14723
  8. Cardoso E, Guidi M, Nauwelaerts N, Nordeng H, Teil M, Allegaert K, Smits A, Gandia P, Edginton A, Ito S, Annaert P, Panchaud A. Safety of medicines during breastfeeding - from case report to modeling: a contribution from the ConcePTION project. Expert Opinion on Drug Metabolism & Toxicology. 2023 Jan-Jun;19(5):269-283. doi: 10.1080/17425255.2023.2221847. Epub 2023 Jun 13. PMID: 37269321.
  9. Yeung CHT, Houle SKD, Anderson PO, Best BM, Dubinsky S, Edginton AN. Addressing maternal medication use during breastfeeding using clinical resources and a novel physiologically based pharmacokinetic model-derived metric: A qualitative study. Frontiers in Pediatrics. 2023;11:1147566. Published 2023 Apr 3. doi:10.3389/fped.2023.1147566
  10. Parmar KR, Lukka PB, Wagh S, Temrikar ZH, Liu J, Lee RE, Braunstein M, Hickey AJ, Robertson GT, Gonzalez-Juarrero M, Edginton A, Meibohm B. Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics. Pharmaceutics. 2023 Jun 17;15(6):1759. doi: 10.3390/pharmaceutics15061759.
  11. Yeung CHT, Beers JL, Jackson KD, Edginton AN. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling. CPT Pharmacometrics & Systems Pharmacology. 2023;12(3):320-332. doi:10.1002/psp4.12908

2022

  1. Gerhart JG, Carreño FO, Edginton AN, Sinha J, Perrin EM, Kumar KR, Rikhi A, Hornik CP, Harris V, Ganguly S, Cohen-Wolkowiez M, Gonzalez D; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2022 Feb;61(2):307-320. doi: 10.1007/s40262-021-01072-4. Epub 2021 Oct 7. PMID: 34617262; PMCID: PMC8813791.
  2. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2022; 1- 1 doi: 10.1111/hae.147230. 
  3. Grassman V, Hajducek D, Edginton AN, Bouskill V, Brown C, Carcao M, Lillicrap D, O’Rourke R, Sinha R, Stoffman J, Wakefield C, Rand ML, Blanchette V. A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors. Blood. 2022;  140 (S1): 8453–8455. doi: 10.1182/blood-2022-160289
  4. Chelle P, Iorio A, Edginton AN. A Personalized Limited Sampling Approach to Better Estimate Terminal Half-life of FVIII concentrates. Journal of Thrombosis and Haemostasis 2022 Jun 26. doi: 10.1111/jth.15803. Epub ahead of print.
  5. Dubinsky, S., Malik, P., Hajducek, D. M., & Edginton, A. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, (2022).  61(7), 997–1012. doi: 10.1007/s40262-022-01121-6
  6. Stitt G, Dubinsky S, Edginton A, et al. Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.  Frontiers in Pediatrics. 2022;10:889958. Published 2022 May 12. doi:10.3389/fped.2022.889958
  7. Gerhart JG, Carreño FO, Loop MS, Lee CR, Edginton AN, Sinha J, Kumar KR, Kirkpatrick CM, Hornik CP, Gonzalez D; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity. Clinical Pharmacology & Therapeutics. 2022 Aug;112(2):391-403. doi: 10.1002/cpt.2618. Epub 2022 May 18. PMID: 35451072; PMCID: PMC9504927.
  8. Gerhart JG, Carreño FO, Edginton AN, et al. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2022;61(2):307-320. doi:10.1007/s40262-021-01072-4
  9. Gerhart JG, Carreño FO, Ford JL, Edginton AN, Perrin EM, Watt KM, Muller WJ, Atz AM, Al-Uzri A, Delmore P, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT Pharmacometrics & Systems Pharmacology. 2022 Jun;11(6):778-791. doi: 10.1002/psp4.12793. Epub 2022 May 2. PMID: 35491971; PMCID: PMC9197535.
  10. Yun YE, Calderon-Nieva D, Hamadeh A, Edginton AN. Development and Evaluation of an In Silico Dermal Absorption Model Relevant for Children. Pharmaceutics. 2022; 14(1):172. Doi: 10.3390/pharmaceutics14010172
  11. Versloot O, Iserman E, Chelle P, et al. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients with Severe Hemophilia. Hemasphere. 2022;6(4):e694. Published 2022 Mar 21. doi:10.1097/HS9.0000000000000694
  12. Ford J, Gerhart J, Edginton AN, Yanovski J, Hon CYY, Gonzalez D. Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents with Obesity. The Journal of Clinical Pharmacology. 2022 ;62(8):960-969. doi:10.1002/jcph.2034
  13. Guimarães M, Maharaj A, Edginton A, Vertzoni M, Fotaki N. Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics. 2022; 14(2):356. https://doi.org/10.3390/pharmaceutics14020356
  14. Malik PRV, Hamadeh A, Edginton AN. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies. Pharmaceutical Research. 2022. 39(2): 239-250.
  15. Gerhart JG, Balevic S, Sinha J, Perrin EM, Wang J, Edginton AN, Gonzalez D. Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations. Frontiers in Pharmacology. 2022 Mar 10;13:818726. doi: 10.3389/fphar.2022.818726. PMID: 35359853; PMCID: PMC8960278.
  16. Gerhart JG, Carreño FO, Ford JL, et al. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT Pharmacometrics & Systems Pharmacology. 2022;11(6):778-791. doi:10.1002/psp4.12793
  17. Hamadeh, A, Troutman, J, Najjar, A, Edginton, AN. A Mechanistic Bayesian Inferential Workflow for Estimation of In Vivo Skin Permeation From In Vitro Measurements. Journal of Pharmaceutical Sciences. 2022; 11(3): 838-851.
  18. Dubinsky S, Watt K, Saleeb S, Ahmed B, Carter C, Yeung CHT, Edginton A.Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature. Clinical Pharmacokinetics. 61(2): 189-229. doi: 10.1007/s40262-021-01085-z.

2021

  1. Chelle P, Hajducek D, Mahdi M, Young S, Iorio A, Silvertown J, Edginton A. External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data. Research and Practice in Thrombosis and Haemostasis. 2021 Nov 2;5(7):e12599. doi: 10.1002/rth2.12599.
  2. Hajducek DM, Primacakti F, Chozie N, et al. Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use. Plasmatology. 2021; 15. doi:10.1177/26348535211062229
  3. Salerno SN, Edginton A, Gerhart JG, et al. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. Clinical Pharmacology & Therapeutics. 2021;109(1):253-262. doi:10.1002/cpt.1990
  4. Yun YE, Edginton AN. Evaluation of models for predicting pediatric fraction unbound in plasma for human health risk assessment. Journal of Toxicology and Environmental Health, Part A. 2021;84(2):67-83. doi:10.1080/15287394.2020.1835761
  5. Yu JK, Iorio A, Chelle P, Edginton AN. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia. 2021;27(3):358-365. doi:10.1111/hae.14292
  6. Yeung CHT, Ito S, Autmizguine J, Edginton AN. Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: A Workflow Applied to Lamotrigine [published correction appears in AAPS J. 2021 Jun 10;23(4):83] [published correction appears in AAPS J. 2021 Jul 13;23(4):93]. AAPS J. 2021;23(4):70. Published 2021 May 17. doi:10.1208/s12248-021-00599-5
  7. Hamadeh A, Troutman J, Edginton AN. Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models. Pharmaceutics. 2021;13(6):807. Published 2021 May 28. doi:10.3390/pharmaceutics13060807
  8. Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG). Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database.Journal of Thrombosis and Haemostasis. 2021; 19 (8): 1896-1906. doi: 10.1111/jth.15395.
  9. Malik PRV, Temrikar ZH, Chelle P, Edginton AN, Meibohm B. Pediatric Dose Selection for Therapeutic Proteins. The Journal of Clinical Pharmacology. 2021 Jun;61 Suppl 1:S193-S206. doi: 10.1002/jcph.1829.
  10. Yun YE, Tornero-Velez R, Purucker ST, Chang DT, Edginton AN. Evaluation of Quantitative Structure Property Relationship Algorithms for Predicting Plasma Protein Binding in Humans. Computational Toxicology. 2021 Feb 1;17:100142. doi: 10.1016/j.comtox.2020.100142.
  11. Ganguly S, Edginton AN, Gerhart JG, et al. Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants. Clinical Pharmacokinetics. 2021;60(12):1591-1604. doi:10.1007/s40262-021-01046-6
  12. Salerno SN, Carreño FO, Edginton AN, Cohen-Wolkowiez M, Gonzalez D. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. Drug Metabolism & Disposition. 2021;49(9):844-855. doi:10.1124/dmd.120.000318

2020

  1. Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. The Journal of Clinical Pharmacology. 2020 Oct;60 Suppl 1:S52-S62. doi: 10.1002/jcph.1713.
  2. Malik PRV, Edginton AN. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants. The Journal of Clinical Pharmacology.2020 Apr;60(4):466-476. doi: 10.1002/jcph.1540. Epub 2019 Nov 14.
  3. Yu JK, Iorio A, Edginton AN. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. Thrombosis Research. 2020 Dec;196:550-558. doi: 10.1016/j.thromres.2020.10.024.
  4. Hajducek DM, Chelle P, Hermans C, Iorio A, McEneny-King A, Yu J, Edginton A. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. Haemophilia. 2020 May; 26(3):384-400. doi: 10.1111/hae.13977. Epub 2020 Apr 13.
  5. Yeung CHT, Fong S, Malik PRV, Edginton AN. Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. Maternal Child Nutrition. 2020 Apr;16(2):e12938. doi: 10.1111/mcn.12938. Epub 2020 Jan 21.
  6. Balbas-Martinez V, Michelet R, Edginton AN, Meesters K, Trocóniz IF, Vermeulen A. Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection.European Journal of Pharmaceutical Sciences. 2019 Feb 1;128:171-179. doi: 10.1016/j.ejps.2018.11.033. Epub 2018 Nov 29. Erratum in: Eur J Pharm Sci. 2020 Feb 15;143:105182.
  7. McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020 Jan;26(1):56-63. doi: 10.1111/hae.13882. Epub 2019 Nov 19.

Publications – Educational Research

Edginton AN, Power M, Stark A, Holbrook J. 2012. Using student feedback to design a more effective clinical biochemistry course component. Currents in Pharmacy Teaching and Learning. In press. 

Edginton AN, Holbrook J. 2010. A Blended Learning Approach to Teaching Basic Pharmacokinetics and the Significance of Face-to-Face Interaction. American Journal of Pharmaceutical Education. 74(5): 88.